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Introduction 
Rapid Cycling Bipolar Disorder (RCBD) is a rare psy-
chiatric disorder that is characterized by at least four 
affective episodes manic, hypomanic or major depres-
sive during the past twelve months [1]. In patients, until 
age 36, mean duration has been documented to be 8 
years [2]. It is very rare in unipolar patients but its prev-
alence is higher in Bipolar Disorder patients [1]. Major 
clinical factors and sleep related factors have been pro-
posed to play an extremely important role in the patho-
genesis of this disorder, which includes subclinical hy-
pothyroidism, anomalies in sleep-wake cycle and obesi-
ty [1, 3]. From a clinical standpoint, a classic presenta-
tion of the patient is female with main diagnosis of Bi-
polar Disorder type 2 with symptoms of depression 
along with cycles of depression, mania and euthymia 
[1]. In addition, these patients can also have other psy-
chiatric comorbidities that include anxiety disorder and 
substance abuse history as well [1].  From the perspec-
tive of pathophysiology, multiple factors have been hy-
pothesized that include genetic factors, thyroid dysfunc-
tion, menstrual disturbance, circadian rhythm disturb-
ances and psychotropic medications [1]. In the follow-
ing paper, we discuss a case report that demonstrates 
RCBD. Furthermore, we also elaborate on its patho-
physiology, therapeutic targets along with molecular 
markers intertwined with neurophysiology that have 
been hypothesized to play an important role in the con-
text of RCBD. 
Methods 
In addition to the case report demonstrated below, we 
performed a literature review of case reports, research 
publications, academic journals and review papers in 
order to gather adequate background information about 
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RCBD. We specifically focused on articles: (1) that 
describe different hypothesis of mechanism of patho-
genesis of RCBD, (2) documented RCBD and various 
medical & psychiatric co-morbidities (3) gender predis-
position of RCBD along with possible blood markers 
that have been linked to RCBD and (4) possible poten-
tial treatment options. 
Case Report 
Patient is a 54-year-old divorced, unemployed Cauca-
sian female with a history of bipolar disorder, Deep 
Vein Thrombosis (DVT), hypothyroidism, hypertension 
currently admitted to inpatient psychiatric facility for 
physical aggression at a group home. Prior to her admis-
sion, patient allegedly got into a fight with the staff and 
other residents in her group home where she was found 
gathering knives from the kitchen. Patient was reported 
to have climbed onto a television stand and attempted to 
pull the television stating “I am Jesus Christ”.  At the 
time of admission, when asked about the events leading 
to her hospitalization, she stated, “False reports that I 
was throwing knifes around. I took care of those ladies. 
They just don’t like me”. She felt that others at the 
group home were conspiring against her. Patient was 
reportedly punched in the face by another patient for 
trying to “baptize someone by pouring orange juice on 
them”. On further interview, patient reports having trou-
ble concentrating while reading, reports reduced sleep 
hours at night, increased energy, racing thoughts. She 
also reported a history of depressive symptoms such as 
poor concentration and feelings of hopelessness/
helplessness owing to the fact that she had a mental 
illness which led her to be suicidal and was admitted 
before 3 months. 
Patient has a long psychiatric history dating back more 
than 30 years starting at the age of 19 when she was 
diagnosed with bipolar disorder and subsequently treat-
ed. Patient had 5 inpatient hospitalizations each during 
the prior two years and 4 inpatient hospitalizations 3 
years prior when patient was found to be manic, hostile, 
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inappropriate, grandiose, tangential, delusional and oth-
er occasions melancholic, depressed attempting to kill 
herself along with one episode of hypomania. In be-
tween, these episodes patient was reportedly at 
“baseline” as per family and was behaving “normally”. 
She also has one prior suicide attempt by trying to over-
dose on Xanax. In addition, patient also has multiple 
felony and misdemeanor charges. Patient denied use of 
alcohol, cannabis, cocaine, benzodiazepines and opioids 
but reported smoking 3 cigarettes/day for the last 5 
years. Patient’s mother had a history of mood disorder. 
Father was an alcoholic. No known family history of 
suicide. Patient reported being a “swimsuit model” 
while she was in her 20s and stated that her mental 
needs hindered her career since she needed frequent 
inpatient hospitalizations and had weight gain secondary 
to antipsychotic medications.  
On physical examination, temperature 96.1ºF, BP 
120/77mmHg, HR 77 beats/min, RR 18 breaths/min. 
Patient was alert, awake and oriented x 3, appearing 
older than stated age, with fair grooming, maintaining 
intense eye contact. Speech was noted to be pressured at 
times with profanities. She was noted to have tremors 
and unsteady gait and orthostatic with systolic blood 
pressure dropping to 90s while standing. Mood was 
described as anxious. Affect was noted to be irritable, 
suspicious and paranoid at times. Thought process was 
disorganized. She denied suicidal ideations and audito-
ry/visual hallucinations. Insight and Judgment were 
poor.  Mini-Mental State Examination (MMSE) 29/30. 
Neurological examination showed unsteady gait. Re-
flexes, coordination and sensory system were within 
normal limits. Cranial nerves 1 through 12 were intact. 
Allergies to Sulfa, Zyprexa, Cogentin and Haldol were 
reported. 
Laboratory findings were consistent with WBC 8.1, 
ANC 5.0, Clozapine Level 519, TSH 2.790 and Lithium 
level of 0.7 upon admission. EKG was read as normal 
sinus rhythm with QTC 400.    
Patient was started on Depakote 1000 mg orally twice 
daily, Clozaril 325 mg orally at night, Lithium 300 mg 
orally twice daily and Ativan 0.5 mg orally three times 
daily. Orthostasis improved with administration of oral 
fluids and reducing the dose of Metoprolol. Regular 
monitoring of renal function, liver function and CBC 
was performed to monitor the side effects of the medi-
cations. Patient was noted to have a worsening creati-
nine of 2.03. Nephrology consulted and patient was 
noted to have chronic kidney disease stage 3 at baseline 
creatinine 1.3-1.5 secondary to lithium nephrotoxicity. 
Patient was further noted to have nephrogenic diabetes 
insipidus and hypertension. Consequently, lithium was 
discontinued. Due to worsening psychosis after discon-
tinuation of Lithium, Depakote was increased to 500 mg 
orally twice daily and 1000 mg at night and Clozaril 
was increased to 350 mg orally at night and Fluphena-
zine 5 mg was added at night. We are considering an 
option of Electroconvulsive therapy (ECT) since the 
patient has shown suboptimal clinical improvement 
despite being on Clozaril. (Serum Clozapine level 855; 
therapeutic serum clozapine level 350-650). 
Discussion 
From the case above we, can see patient had minimum 
of 4 mood episodes in the past 12 month period which 
included mania, hypomania and depression symptoms 
along with partial remission for at least 2 months as per 
family which from DSM 5 criteria is diagnostic for 
RCBD [4,5,6]. Multiple risk factors have been elucidat-
ed to play an important role in development of RCBD 
which include female gender [7], previous suicide at-
tempts, early age of onset, atypical depression symp-
toms and high antidepressant use [8,9,10], majority of 
which were present in the case report demonstrated 
above.   
Even though the exact mechanism of pathogenesis is not 
known several extrapolations and hypothesis can be 
generated. From a neurobiological standpoint, imaging 
studies in humans have demonstrated atrophy in the 
ventral prefrontal cortex along with gray matter degen-
eration in orbital pre-frontal cortex, cingulate cortex and 
parahippocampus [11, 12]. In addition, many important 
bio-psycho-social factors have been hypothesized to be 
possible contributors to RCBD that include history of 
family neglect, intra-familial conflicts and child abuse 
[13]. Many genetic factors that include low expression 
of COMT gene that codes for Catechol-O-Methyl 
Transferase gene [14] and P2RX7 gene have been linked 
to RCBD [15]. Furthermore, enzyme anomalies in ara-
chidonic and prostaglandin pathway have been shown to 
play an important role in RCBD; more specifically low 
expression of enzyme Prostaglandin D synthase 
(PTGDS), Prostaglandin D Synthase which converts 
Prostaglandin H2 to Prostaglandin D2 [16,17]. Age and 
gender adjusted analysis of mRNA expression of 
PTGDS in peripheral mononuclear cells has been shown 
to be significantly correlated to high incidence RCBD 
[16] Furthermore, BDNF (Brain Derived Neurotropic 
Factor) has been shown to associated with chronic 
RCBD, specifically in all three phases: euthymic, de-
pression, manic/hypomanic phase [18]. Interestingly, 
patients with RCBD Type 1, have been to have signifi-
cant cell membrane alterations which leads to increase 
choline containing compounds like glycerophosphocho-
line and phosphocholine [19]. Finally, an interesting 
case report of Anti-AMPA receptor-mediated encephali-
tis in a Turner Syndrome patient who developed RCBD 
has been documented [20]. 
Interestingly, many significant comorbid findings have 
been reported in RCBD that includes anxiety disorder 
[21], hyper-homocystenemia which increases risk of 
recurrent strokes [22], obesity [23], high suicide risk 
[24], migraines [25] and high level of inflammatory 
markers like interleukin 6 and 18 which could potential-
ly contribute to mania and hypomania [26]. Based on 
current hypothesis for depression [27], the enzyme IDO 
(Indolamine 2,3 Dioxygenase) seems to upregulated 
secondary to high interleukin production in patients. 
This leads to depletion of tryptophan which in turn de-
creases serotonin and increases quinolonic acid which 
potentially leads to increased NMDA receptor activation 
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[27] and lead to depression (Figure 1). So it possible 
that interleukins 6 and 18 mentioned above could be 
further contributing to exacerbation of depression in 
RCBD cases. 
From a therapeutic standpoint, previous research has 
shown multiple drugs to effective. For instance, 
Lamotrigine has been known to increase the amount of 
euthymia in patients with RCBD as compared to place-
bo [28, 29]. In addition Pramiprexole has been shown to 
alleviate resistant depression in RCBD patients [30]. 
Furthermore, continuation of lithium and ECT has been 
shown to stabile the mood in patients with RCBD [31]. 
In patients with co-morbid conditions like hypothyroid-
ism, Levothyroxine augmentation therapy was shown to 
resolve RCBD symptoms in patients [32]. Finally, Keta-
mine has also been shown to be extremely useful in 
RCBD patients with active suicidal ideations [33].  
Conclusion 
Hereby, we have demonstrated a case report along with 
a literature review which focusing on background infor-
mation, pathogenesis, biomarkers and potential treat-
ment options for Rapid Cycling Bipolar Disorder.   
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